# Combined top 10 from each PICO category for lijecnicki vjesnik-139-365_cleaned.json

## Population

1. (Patients, score 8) ne crizotinib versus chemo-
Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus
docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer
non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled trial.
chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2

2. (Patients, score 8) ;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus
docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer
non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled trial.
chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65.
Study Group. J Clin

3. (Patients, score 7) čkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA non-small cell lung cancer. J Clin On-
prema preporuci multidisciplinarnog tima). col 2012;30:172–8.
8. Gilligan D, Nicolson M, Smith I i sur. Preoperative chemotherapy in
Diseminirana/neresektabilna lokalno uznapredovala patients with resectable non-small cell lung cancer: results of the MRC
bolest – pauza u liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up-
date of systematic review. Lancet 2007;369:1929–37.
detekcije progresije bolesti
9. NSCLC Meta-analysis Collaborative Gro

4. (Patients, score 7) 33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing
12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo-
radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51.
13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall
versus s

5. (Patients, score 7) tice Guidelines for diagnosis, treatment
surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27.
20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy
tion therapy on survival in patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life
II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br J Cancer 2006;
apy: the adjuvant Navelbine International Trialist A

6. (Patients, score 7) stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a
vinorelbine plus cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;
resected stage IB

7. (Patients, score 7) 13:239–46.
analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus cisplatin-based che-
23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX-
cisplatin versus observation in patients with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from two
IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51.
Trialist Association [ANITA]): a randomised controlled trial. Lancet 45.

8. (Patients, score 7) taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10):
24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin
46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst-
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
line treatment for patients with advanced EGFR mutation-positive
Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel
open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):
plus carboplatin compared with observatio

9. (Patients, score 7) 2011;12(8):
plus carboplatin compared with observation in stage IB non-small-cell
lung cancer: CALGB 9633 with the Cancer and Leukemia Group B,
47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat-
Radiation Therapy Oncology Group, and North Central Cancer Treat-
ment for patients with advanced non-small-cell lung cancer with acti-
ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51.
vating epidermal growth factor receptor mutation: Review of the evi-
26. Sederholm C, Hillerdal G, Lambert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57.
citabine p

10. (Patients, score 7) 8380–8. analysis. J Natl Cancer Inst 2013;105:595–605.
27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as
agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small-
lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la-
28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:1236–44.
tio

## Intervention

1. (Therapy, score 11) atients who are nonprogressive after two cycles of
adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non small-cell lung cancer. J Clin
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-sm

2. (Treatment, score 9) rapy
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol
Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7.
37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol-
16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi-
ogy in Eastern Cooperative Group Study E4599 of bevacizumab with
tant versus sequential radiochemotherapy in locally advanced non-
paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho-

3. (Treatment, score 9) ell lung cancer. J Clin
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a
vinorelbine plus cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2

4. (Treatment, score 9) i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6.
pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non-
1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9.
58. Nagano T, Kim YH, Goto K i sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously
lapsed non-small-cell lung cancer.

5. (Therapy, score 9) nd Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:
31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo-
Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Ritt

6. (Treatment, score 8) arinis F, Dediu M i sur. PARAMOUNT: final overall
versus sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of maintenance pemetrexed ver-
mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J
14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902.
chemoradiation for stage III non-small cell lung cancer: randomized 35.

7. (Treatment, score 8) 2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10):
24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin
46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst-
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
line treatment for patients with advanced EGFR mutation-positive
Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel
open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):
plus carboplatin compared wi

8. (Treatment, score 8) itabine in advanced non-
study of two cisplatin-based regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J
in advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52.
pean Organization for Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:
31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regi

9. (Treatment, score 8) T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40.
cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for
Oncol 2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer
57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6.
pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA app

10. (Treatment, score 8) d 2005;353:
59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32.
sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the
small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869.
60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa-
Advanced Non

## Comparator

1. (Placebo, score 3) re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously
lapsed non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353:
59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32.
sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the
small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. ta

2. (Placebo, score 2) of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall
versus sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of maintenance pemetrexed ver-
mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J
14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902.
chemoradiation for stage III non-

3. (Placebo, score 2) umab for non-small-cell lung cancer. N Engl J Med 2006;355:
15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of
36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin plus
sequential chemoradiotherapy compared with concurrent chemoradio-
gemcitabine with either placebo or bevacizumab as fi rst-line therapy
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol
Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7.
37. S

## Outcome

1. (Outcome, score 3) ith N0 or N1 (less than hilar)
Ostale pretrage prema kliničkoj indikaciji (PET samo non-small cell carcinoma: results of the American College of Surgery
Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141(3):
prema preporuci multidisciplinarnog tima).
6. Baumann P, Nyman J, Hoyer M i sur. Outcome in a prospective phase
Diseminirana/neresektabilna lokalno uznapredovala
II trial of medically inoperable stage I non-small-cell lung cancer pa-
bolest u fazi aktivnog liječenja tients treated with stereotactic body radiotherapy. J Clin Oncol 2009;
Kontrola učinka liječenja svakih 6 – 8 tjedana (re

2. (Effect, score 1) l lung pemetrexed according to NSCLC histology: a review of two phase III
cancer: a phase III randomised controlled trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63.
379–86. 33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing
12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo-
radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–4

